Literature DB >> 6378238

Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.

N Babudri, B Pani, M Tamaro, C Monti-Bragadin, F Zunino.   

Abstract

The mutagenic and cytotoxic activity of two newly synthesized doxorubicin derivatives and of one daunorubicin derivative were studied in V79 Chinese hamster cells and bacteria (Salmonella typhimurium and Escherichia coli). The results showed that all the compounds tested were cytotoxic and mutagenic for both prokaryotic and eukaryotic cells. However, in both systems, the two 4-desmethoxy- and the 4'-desoxy-derivatives were more active than the parent compounds, indicating that modifications in the aglycone or in the sugar moiety can produce appreciable changes in the biological properties of the anthracycline antibiotics. The in vitro activities observed in this study correlated with the in vivo antitumour potency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378238      PMCID: PMC1976926          DOI: 10.1038/bjc.1984.143

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Affinity of adriamycin to phospholipids. A possible explanation for cardiac mitochondrial lesions.

Authors:  M Duarte-Karim; J M Ruysschaert; J Hildebrand
Journal:  Biochem Biophys Res Commun       Date:  1976-07-26       Impact factor: 3.575

2.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

Review 3.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

Review 4.  Pedigrees of some mutant strains of Escherichia coli K-12.

Authors:  B J Bachmann
Journal:  Bacteriol Rev       Date:  1972-12

5.  Interaction of daunomycin and its derivatives with DNA.

Authors:  F Zunino; R Gambetta; A Di Marco; A Zaccara
Journal:  Biochim Biophys Acta       Date:  1972-09-14

6.  Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.

Authors:  W D Meriwether; N R Bachur
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

7.  Daunomycin inhibition of DNA and RNA synthesis.

Authors:  A Theologides; J W Yarbro; B J Kennedy
Journal:  Cancer       Date:  1968-01       Impact factor: 6.860

8.  Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin.

Authors:  H Marquardt; F S Philips; S S Sternberg
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

9.  A comparative study of different experimental protocols for mutagenesis assays with the 9-azaguanine resistance system in cultured Chinese hamster cells.

Authors:  A Abbondandolo; S Bonatti; C Colella; G Corti; F Matteucci; A Mazzaccaro; G Rainaldi
Journal:  Mutat Res       Date:  1976-11       Impact factor: 2.433

10.  Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic.

Authors:  F Arcamone; G Franceschi; S Penco; A Selva
Journal:  Tetrahedron Lett       Date:  1969-03       Impact factor: 2.415

View more
  3 in total

1.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 2.  Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?

Authors:  J Huk; M Blumauerova
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

3.  A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin.

Authors:  Claire Amaris Hobson; Lucile Vigué; Mélanie Magnan; Benoit Chassaing; Sabrine Naimi; Benoit Gachet; Pauline Claraz; Thomas Storme; Stephane Bonacorsi; Olivier Tenaillon; André Birgy
Journal:  Front Cell Infect Microbiol       Date:  2022-06-01       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.